Teva posts 13% profits hike; J&J asks FDA for another new Xarelto use;

 @FiercePharma: New DSM won't make grief an illness. Panel also cuts two proposed diagnoses: RE psychosis, anxiety/depression--NYT. Article | Follow @FiercePharma

> In CEO Shlomo Yanai's last earnings report before the advent of Jeremy Levin (photo), Teva Pharmaceutical Industries ($TEVA) said profit rose 13% to $859 million, on growth in both branded and generic drugs. Report

> Johnson & Johnson ($JNJ) asked the FDA to approve another new use for its anticoagulant drug Xarelto, this time to reduce the risk of stent-related blood clots. Report

> U.K. regulators won't require drug companies to troll the Internet for adverse-event reports, and nor will they be required to monitor social media, except on sites and pages they control. Report

> India's Zydus Cadila is reportedly in buyout talks with Strides Arcolab; the deal would involve Strides' domestic generics business. Report

> Savient Pharmaceuticals posted a bigger-than-expected loss for the first quarter, thanks to high sales-and-marketing costs on its gout drug Krystexxa, which provided 90% of its revenue. Report

> The FDA said Celgene ($CELG) added label warnings to its blood cancer drug Revlimid, cautioning patients and doctors that users bear a higher risk of certain other cancers. Report

> Merck KGaA's cancer drug Erbitux failed a study in colon cancer. Report

> Japanese private equity firm Unison Capital beat out genericsmaker Mylan ($MYL) and other private-equity bidders for drugmaker Showa Yakuhin Kako. Report

Biotech News

 @FierceBiotech: Third Rock's Levin calls for teamwork in personalized medicine by @DamianFierce. Report | Follow @FierceBiotech

 @RyanMFierce: GSK's pursuit of HGSI has gone hostile as GSK goes directly to HGS investors with $2.6B tender offer. News | Follow @RyanMFierce

> FDA advisers snub Regeneron drug for gout. News

> Support seen for U.S. plan to speed nods for 'breakthrough' drugs. Article

> GSK raises fists in $2.6B hostile bid for Human Genome Sciences. Report

@FierceMedDev: Covidien bought Maya Medical, the maker of a renal denervation treatment, and barely acknowledged it. Item | Follow @FierceMedDev

> Hygieia releases study results for its new hand-held insulin device. Article

> St. Jude armed with FDA approval for Ellipse ICD. Report

> Given Imaging revenue jumps overall, due to Americas PillCam sales. More

> Covidien grabs Maya Medical for $60M-plus. Item

Drug Delivery News

 @DamianFierce: The coming onslaught of blockbuster knockoffs could be a huge opportunity for drug delivery companies. News | Follow @DamianFierce

> Charge-changing nanoparticles can help kill resistant bacteria. More

> pSivida gets U.K. nod for behind-the-eye treatment. Article

> Echo's trandsdermal tech gets positive results, TV time. News

> Patent cliff could create need for novel delivery tech. Item

> MonoSol, Midatech tout positive Phase I for insulin film. Story

Biomarkers News

> Targeted therapies need cost-effective biomarkers. More

> DNA changes could predict prostate cancer relapse. Article

> 15-minute test could tag Alzheimer's. Story

> Biosignatures fingerprint tuberculosis and sarcoidosis. Story

And Finally... Aspirin worked as well as warfarin at warding off clots in congestive heart failure patients, a study found. Report